UTH Stock Overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$216.60 |
| 52 Week High | US$235.40 |
| 52 Week Low | US$189.80 |
| Beta | 0.55 |
| 1 Month Change | 1.64% |
| 3 Month Change | 7.98% |
| 1 Year Change | 5.97% |
| 3 Year Change | 23.07% |
| 5 Year Change | 134.19% |
| Change since IPO | 1,103.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| UTH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -4.3% | -2.5% |
| 1Y | 6.0% | -19.4% | -0.4% |
Return vs Industry: UTH exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: UTH exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| UTH volatility | |
|---|---|
| UTH Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UTH has not had significant price volatility in the past 3 months.
Volatility Over Time: UTH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| UTH fundamental statistics | |
|---|---|
| Market cap | €10.37b |
| Earnings (TTM) | €922.56m |
| Revenue (TTM) | €2.18b |
11.2x
P/E Ratio4.8x
P/S RatioIs UTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UTH income statement (TTM) | |
|---|---|
| Revenue | US$2.33b |
| Cost of Revenue | US$257.50m |
| Gross Profit | US$2.07b |
| Other Expenses | US$1.09b |
| Earnings | US$984.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.93 |
| Gross Margin | 88.94% |
| Net Profit Margin | 42.31% |
| Debt/Equity Ratio | 11.7% |
How did UTH perform over the long term?
See historical performance and comparison